Abbott Resolves Portion of Preterm Formula Litigation, Reducing Legal Overhang

What happened

Abbott has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals regarding its specialty formulas for preterm infants, as announced on August 20, 2026. The settlements resolve a portion of the litigation that had been an overhang on the Nutrition segment, which has already been struggling with lower volumes and pricing actions. Abbott reiterated that it and the medical community stand by the safety of preterm infant formulas, and there is no reliable scientific evidence linking them to necrotizing enterocolitis. This reduces legal uncertainty but does not eliminate all litigation risk, as other cases may remain, and the company faces broader challenges in Nutrition and diagnostics. The news is mildly positive for the stock but does not change the fundamental view that ABT is fairly valued at $107.3 with a WAIT rating.

Implication

The settlement reduces tail risk and may allow management to focus on stabilizing Nutrition, but it does not address the segment's volume declines or pricing pressure. Investors should continue to monitor nutrition trends and Exact Sciences integration; the stock remains a WAIT with better entry near $98.

Thesis delta

The settlement removes a downside catalyst but does not alter the base case. The investment thesis remains unchanged: durable medtech franchises offset by nutrition softness and Exact dilution; continue to wait for $98 entry.